430 related articles for article (PubMed ID: 10410186)
1. The evolving role of platelet glycoprotein IIb/IIIa inhibitors in the management of acute coronary syndromes.
Stringer KA
Ann Pharmacother; 1999 Jun; 33(6):712-22. PubMed ID: 10410186
[TBL] [Abstract][Full Text] [Related]
2. Safety of glycoprotein IIb-IIIa inhibitors: A heart surgeon's perspective.
Dyke CM
Am Heart J; 1999 Oct; 138(4 Pt 2):307-16. PubMed ID: 10502236
[TBL] [Abstract][Full Text] [Related]
3. Current role of platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes.
Bhatt DL; Topol EJ
JAMA; 2000 Sep; 284(12):1549-58. PubMed ID: 11000650
[TBL] [Abstract][Full Text] [Related]
4. Platelet inhibitors in non-ST-segment elevation acute coronary syndromes and percutaneous coronary intervention: glycoprotein IIb/IIIa inhibitors, clopidogrel, or both?
Silva MA; Donovan JL; Gandhi PJ; Volturo GA
Vasc Health Risk Manag; 2006; 2(1):39-48. PubMed ID: 17319468
[TBL] [Abstract][Full Text] [Related]
5. Platelet glycoprotein IIb/IIIa-receptor inhibitors in patients with acute coronary syndromes or undergoing percutaneous coronary interventions: a review.
Truong KM; Amankwa K; Kucukarslan S
Clin Ther; 2001 Aug; 23(8):1145-65; discussion 1129. PubMed ID: 11558855
[TBL] [Abstract][Full Text] [Related]
6. Glycoprotein IIb/IIIa receptor inhibitors in percutaneous coronary intervention and acute coronary syndrome.
Crouch MA; Nappi JM; Cheang KI
Ann Pharmacother; 2003 Jun; 37(6):860-75. PubMed ID: 12773077
[TBL] [Abstract][Full Text] [Related]
7. Overview of clinical trials of glycoprotein IIb-IIIa inhibitors in acute coronary syndromes.
Harrington RA
Am Heart J; 1999 Oct; 138(4 Pt 2):276-86. PubMed ID: 10502233
[TBL] [Abstract][Full Text] [Related]
8. Platelet glycoprotein IIb/IIIa receptor antagonists in cardiovascular disease.
Vorchheimer DA; Badimon JJ; Fuster V
JAMA; 1999 Apr; 281(15):1407-14. PubMed ID: 10217057
[TBL] [Abstract][Full Text] [Related]
9. [The clinical use of the GPIIb/IIIa inhibitors eptifibatide and tirofiban in the treatment of acute coronary syndromes of the "non-ST elevation" type].
Galli M; Maggioni AP; Vassanelli C; Tavazzi L
Ital Heart J Suppl; 2000 Feb; 1(2):202-11. PubMed ID: 10731377
[TBL] [Abstract][Full Text] [Related]
10. Antiplatelet intervention in acute coronary syndrome.
Arora RR; Rai F
Am J Ther; 2009; 16(5):e29-40. PubMed ID: 19092648
[TBL] [Abstract][Full Text] [Related]
11. An overview of the results of clinical trials with glycoprotein IIb/IIIa inhibitors.
Adgey AA
Eur Heart J; 1998 Apr; 19 Suppl D():D10-21. PubMed ID: 9597518
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic potential of platelet glycoprotein IIb/IIIa receptor antagonists in the management of ischemic stroke.
Lapchak PA; Araujo DM
Am J Cardiovasc Drugs; 2003; 3(2):87-94. PubMed ID: 14727935
[TBL] [Abstract][Full Text] [Related]
13. Glycoprotein IIb/IIIa receptor antagonists in the management of cardiovascular diseases.
Chong PH
Am J Health Syst Pharm; 1998 Nov; 55(22):2363-86. PubMed ID: 9825033
[TBL] [Abstract][Full Text] [Related]
14. The emerging role of platelet glycoprotein IIb/IIIa inhibitors in managing high-risk patients with non-ST segment elevation acute coronary syndromes.
Bolognese L
Curr Med Res Opin; 2007 Jun; 23(6):1217-26. PubMed ID: 17559721
[TBL] [Abstract][Full Text] [Related]
15. [Platelet glycoprotein IIb/IIIa inhibitors in coronary artery disease].
Auer J; Berent R; Lassnig E; Weber T; Maurer E; Eber B
Herz; 2003 Aug; 28(5):393-403. PubMed ID: 12928738
[TBL] [Abstract][Full Text] [Related]
16. Upstream use of small-molecule glycoprotein iib/iiia inhibitors in patients with non-ST-segment elevation acute coronary syndromes: a systematic overview of randomized clinical trials.
Tricoci P; Newby LK; Hasselblad V; Kong DF; Giugliano RP; White HD; Théroux P; Stone GW; Moliterno DJ; Van de Werf F; Armstrong PW; Prabhakaran D; Rasoul S; Bolognese L; Durand E; Braunwald E; Califf RM; Harrington RA
Circ Cardiovasc Qual Outcomes; 2011 Jul; 4(4):448-58. PubMed ID: 21712522
[TBL] [Abstract][Full Text] [Related]
17. Combining enoxaparin and glycoprotein IIb/IIIa antagonists for the treatment of acute coronary syndromes: final results of the National Investigators Collaborating on Enoxaparin-3 (NICE-3) study.
Ferguson JJ; Antman EM; Bates ER; Cohen M; Every NR; Harrington RA; Pepine CJ; Theroux P;
Am Heart J; 2003 Oct; 146(4):628-34. PubMed ID: 14564315
[TBL] [Abstract][Full Text] [Related]
18. Optimal use of platelet glycoprotein IIb/IIIa receptor antagonists in patients undergoing percutaneous coronary interventions.
Starnes HB; Patel AA; Stouffer GA
Drugs; 2011 Oct; 71(15):2009-30. PubMed ID: 21985168
[TBL] [Abstract][Full Text] [Related]
19. PlA(1)/PlA(2) polymorphism does not influence response to Gp IIb-IIIa inhibitors in patients undergoing coronary angioplasty.
Verdoia M; Pergolini P; Camaro C; Restifo M; Rolla R; Schaffer A; Di Giovine G; Marino P; Bellomo G; Suryapranata H; De Luca G;
Blood Coagul Fibrinolysis; 2013 Jun; 24(4):411-8. PubMed ID: 23412353
[TBL] [Abstract][Full Text] [Related]
20. Present and evolving role of eptifibatide in the treatment of acute coronary syndromes.
Tricoci P; Newby LK; Kandzari DE; Harrington RA
Expert Rev Cardiovasc Ther; 2007 May; 5(3):401-12. PubMed ID: 17489665
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]